GSK to buy US biotech firm IDRx for up to $1.15 billion

2 days ago · British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of …

$1.15
OFF

GSK To Buy US Biotech Firm IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago · British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of …

reuters.com

$1.15
OFF

GSK To Buy U.S. Rare Tumor Specialist IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago · GSK is buying privately-owned U.S. rare-tumor specialist IDRx for up to $1.15 billion, boosting its gastrointestinal cancer portfolio. The pharmaceutical giant said Monday that it will …

morningstar.com

$1.15
OFF

GSK To Acquire IDRx For $1.15bn — Financier Worldwide

2 weeks from now

1 day ago · Drug manufacturer GSK has agreed to acquire US biopharmaceutical firm IDRx, which is developing a therapy for the treatment of gastrointestinal stromal tumours (GIST). …

financierworldwide.com

$1.15
OFF

GSK To Buy US Cancer Biotech IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago · GSK Plc agreed to buy US biotech IDRx for as much as $1.15 billion to gain new cancer medicines.. The UK drugmaker will pay $1 billion upfront for IDRx, whose lead drug for …

bloomberg.com

$1.15
OFF

GSK Acquiring US-Based IDRx For Up To $1.15 Billion - MSN

2 weeks from now

GSK (GSK) has agreed to acquire Boston-based IDRx for up to $1.15 billion as the British drugmaker looks to expand its gastrointestinal cancer portfolio, the companies said Monday. …

msn.com

$1.15
OFF

GSK To Buy Boston-based IDRx For $1.15 Billion - MSN

2 weeks from now

GSK (NYSE:GSK) finalized the deal to acquire Boston-based, clinical-stage biopharmaceutical company—IDRx for a total of up to $1.15 billion cash consideration. Under the agreement …

msn.com

$1.15
OFF

GSK Buys American Firm Developing Therapy For Rare Tumours

2 weeks from now

GSK has agreed an acquisition worth up to $1.15 billion for IDRx, an American biopharmaceutical company. ... confirmed on Monday that it had agreed to buy the clinical-stage company based …

thetimes.com

$1.15
OFF

GSK To Buy US Biotech Firm IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago · British drugmaker GSK agrees to acquire Boston-based biopharmaceutical firm IDRx for up to $1.15 billion, with an initial $1 billion payment. IDRx develops a treatment for …

indiatimes.com

$1
OFF

GSK Nearing Deal To Acquire US Biotech IDRx For Up To $1 Billion

2 weeks from now

Jan 8, 2025 · GSK to Buy US-based IDRx for Up to $1.15 Billion to Boost Gastrointestinal Cancer Pipeline Jan. 13: MT GSK to Buy US-based IDRx for $1.15 Billion in Boost for Gastrointestinal …

marketscreener.com

$1.15
OFF

GSK To Buy US Cancer Biotech IDRx For Up To $1.15 Billion - Deccan …

2 weeks from now

2 days ago · The UK drugmaker will pay $1 billion upfront for IDRx, whose lead drug for gastrointestinal tumors shows potential against mutations that currently leave patients with few …

deccanherald.com

$1
OFF

GSK Nears $1 Billion Deal For Biotech Company IDRx - BNN …

2 weeks from now

6 days ago · (Bloomberg) -- GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its …

bnnbloomberg.ca

$1.15
OFF

GSK To Buy US Biotech Firm IDRx For Up To $1.15 Billion - MSN

2 weeks from now

(Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of …

msn.com

$1.15
OFF

GSK To Acquire Oncology Firm IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago · -- GSK has agreed to acquire oncology company IDRx for up to $1.15 billion, the companies said Monday. ... GSK to Buy US-based IDRx for Up to $1.15 Billion to Boost …

marketscreener.com

$1
OFF

GSK Swooping To Buy US Biotech IDRx For $1bn - Report

2 weeks from now

Jan 8, 2025 · UK pharma giant GSK PLC is close to buying US biotech startup IDRx for $1 billion to boost its cancer drug business, the Financial Times has reported. ...

proactiveinvestors.co.uk

$1
OFF

Is GSK Prepping A $1bn Takeover Bid For IDRx? | Pharmaphorum

2 weeks from now

6 days ago · GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare gastrointestinal stromal tumour (GIST).

pharmaphorum.com

$1.15
OFF

GSK To Buy US Biotech Firm IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago · (Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a …

investing.com

$1
OFF

GSK Swooping To Buy US Biotech IDRx For $1bn - Report

2 weeks from now

Jan 8, 2025 · UK pharma giant GSK PLC is close to buying US biotech startup IDRx for $1 billion to boost its cancer drug business, the Financial Times has reported. Backed by a raft of …

proactiveinvestors.com

$1.15
OFF

GSK Acquiring US-Based IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago · -- GSK has agreed to acquire Boston-based IDRx for up to $1.15 billion as the British drugmaker looks to expand its gastrointestinal cancer portfolio, the companies said Monday. ...

marketscreener.com

$1.15
OFF

GSK To Buy US-based IDRx For $1.15 Billion In Boost For ...

2 weeks from now

2 days ago · GSK Acquiring US-Based IDRx for up to $1.15 Billion 13/01/2025 GSK PLC: GSK enters agreement to acquire IDRx, Inc. 13/01/2025 GSK to Bolster Gastrointestinal Cancer …

cbonds.com

$1.15
OFF

GSK Reportedly In Advanced Talks To Buy US Biotech IDRx

2 weeks from now

6 days ago · GSK to Buy U.S. Rare Tumor Specialist IDRx for Up to $1.15 Billion Jan. 13: DJ GSK to buy US biotech firm IDRx for up to $1.15 billion Jan. 13: RE GSK plc entered into an …

marketscreener.com

$1.15
OFF

GSK To Buy US-based IDRx For Up To $1.15 Billion To Boost ...

2 weeks from now

2 days ago · GSK to Buy US-based IDRx for Up to $1.15 Billion to Boost Gastrointestinal Cancer Pipeline January 13, 2025 at 02:40 am EST Share This article is reserved for members ...

marketscreener.com

$1.15
OFF

GSK To Buy US Biotech Firm IDRx For Up To $1.15 Billion - U.S. News

2 weeks from now

2 days ago · (Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a …

usnews.com

$1.15
OFF

GSK To Buy US-based IDRx For $1.15 Billion In Boost For ...

2 weeks from now

2 days ago · GSK to Buy US-based IDRx for $1.15 Billion in Boost for Gastrointestinal Cancer Pipeline January 13, 2025 at 02:22 am EST Share This article is reserved for members . To …

marketscreener.com

FAQs about GSK to buy US biotech firm IDRx for up to $1.15 billion Coupon?

Does GSK buy idrx?

British drugmaker GSK agrees to acquire Boston-based biopharmaceutical firm IDRx for up to $1.15 billion, with an initial $1 billion payment. IDRx develops a treatment for gastrointestinal stromal tumours, contributing to GSK's expanding portfolio in gastrointestinal cancers amid its vaccine business challenges. ...

How much does GSK pay for idrx-42?

Under the agreement signed by both companies, GSK (GSK) will pay $1 billion upfront, with the potential for an additional $150 million success-based regulatory approval milestone payment. The acquisition includes lead molecule, IDRX-42, a highly selective KIT TKI being developed as a first- and second-line therapy for the treatment of GIST. ...

Who owns idrx?

IDRx counts Andreessen Horowitz, Casdin Capital, Nextech Invest, Forge Life Science Partners, and RA Capital Management among its investors. GSK (GSK) has agreed to acquire Boston-based IDRx for up to $1.15 billion as the British drugmaker looks to expand its gastrointestinal cancer portfolio, the companies said Monday. ...

Will GSK's idrx-42 deal support its growth plans through 2031?

GSK said it expects the deal to support its growth plans through 2031 and beyond. In November, IDRx said that IDRX-42 showed a "promising" anti-tumor activity in a phase 1/1b trial, with a 29% objective response rate across all patients and a 53% rate in second-line patients. ...

Will GSK advance idrx-42 for patients with Gist?

"We are looking forward to working with GSK to advance IDRX-42 for patients with GIST given there have been no major advances to the standard of care for almost 20 years," IDRx Chief Executive Tim Clackson said. ...

Is idrx a Merck deal?

IDRx launched in 2022 with license agreements with Germany’s Merck KGaA and Blueprint Medicines. IDRx’s leading medicine was part of the Merck deal. Under Monday’s agreement, GSK will have to pay success-based milestone payments and tiered royalties owed to Merck. ...